Alimera resubmits Iluvien new drug application

Alimera Sciences has resubmitted its new drug application for Iluvien to the U.S. Food and Drug Administration, according to a press release. The company will provide information on the FDA’s acceptance of the resubmission and a Prescription Drug User Fee Act date as it becomes available, the release said.